Sichuan Biokin Pharmaceutical Co. Ltd. A

688506 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

250.05CNY-2.67 (-1.06%)

Price History

Full chart

Market Stats

Previous Close252.72

Open253.31

Day Range248.25 – 253.36

52-Week Range200.10 – 404.00

Volume1.05M

Market Cap99.92B

P/E (TTM)0.00

Forward P/E0.00

EPS-3.80

Dividend Yield0.00%

Beta-0.07

50-Day Avg276.72

200-Day Avg281.11

About

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, manufacture, and sale of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Yi Zhu
Employees3.43K
HeadquartersBlock B, Gaoxin International Plaza, Chengdu, China, China
Websitehttps://www.baili-pharm.com

Leadership

Dr. Yi ZhuChairman, GM & Chief Scientific Officer · b. 1963
Ms. Suya ZhangCFO, Executive Deputy GM, Accounting Supervisor & Director · b. 1955
Dr. Hai ZhuExecutive Director · b. 1988
Mr. Shi ZhuoDeputy GM & Executive Director · b. 1985
Dr. Weili WanDeputy GM & Executive Director · b. 1989
Yong HeDeputy General Manager · b. 1975

Financials

Income Statement

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	796.73M	703.28M	561.87M	5.82B	2.52B
Growth (%)	-	-11.73%	-20.11%	+936.31%	-56.72%
Cost of Revenue	197.73M	232.74M	229.28M	264.39M	232.40M
Gross Profit	599.01M	470.54M	332.59M	5.56B	2.29B
Gross Margin	75.18%	66.91%	59.19%	95.46%	90.78%
Operating Expense	692.28M	723.49M	1.07B	1.81B	3.03B
Operating Income	-93.28M	-252.95M	-742.23M	3.74B	-743.36M
Operating Margin	-11.71%	-35.97%	-132.10%	64.29%	-29.50%
EBITDA	-	-203.65M	-679.61M	4.10B	-532.77M
EBITDA Margin	-	-28.96%	-120.96%	70.42%	-21.14%
Net Income	-99.99M	-282.38M	-780.50M	3.71B	-1.05B
Net Income Margin	-12.55%	-40.15%	-138.91%	63.67%	-41.81%
R&D	278.60M	375.02M	746.23M	1.44B	2.51B
R&D as % of Total Revenue	34.97%	53.32%	132.81%	24.78%	99.75%
Interest Expense	8.69M	22.48M	24.68M	42.52M	85.07M
Interest Expense % of Total Revenue	1.09%	3.20%	4.39%	0.73%	3.38%

Balance Sheet

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	951.46M	1.99B	1.43B	7.14B	11.45B
Total Liabilities	619.61M	1.06B	1.27B	3.25B	4.83B
Total Equity	331.85M	933.89M	151.87M	3.89B	6.62B
Cash	154.22M	1.00B	403.96M	3.22B	5.18B
Net Debt	57.01M	-	55.07M	-	-

Cash Flow

Currency: CNY	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-135.03M	-258.65M	-615.35M	4.06B	-798.40M
Capital Expenditure	44.60M	34.56M	81.94M	83.86M	263.81M
Free Cash Flow	-179.63M	-293.21M	-697.29M	3.97B	-1.06B
Dividends Paid	26.97M	12.59M	18.77M	38.36M	78.38M
FCF to OCF	133.03%	113.36%	113.32%	97.93%	133.04%
Dividend Paid to FCF	-15.02%	-4.29%	-2.69%	0.97%	-7.38%

Earnings

Report Date	Mar 31, 2023
EPS Estimate	-
EPS Actual	-0.42
Surprise	-
Timing	-

Key Statistics & Ratios

Market Cap99.92B

Enterprise Value102.73B

Trailing P/E0.00

Forward P/E0.00

Price / Sales39.40

Price / Book22.23

EPS-3.80

Book Value11.17

Revenue (TTM)2.54B

Gross Profit (TTM)2.27B

EBITDA-1.14B

Profit Margin-62.02%

Operating Margin-926.18%

Return on Equity-42.46%

Return on Assets-8.45%

Shares Outstanding412.87M

Shares Float78.15M

Beta-0.07

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%